Update on Biosimilars

Are less expensive versions of costly biologic drugs fulfilling theirpromises?

If you are on a biologic drug for an inflammatory form of arthritis, such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, you may have heard of biosimilars. The first biosimilar agent for the treatment of inflammatory arthritis was approved by the Food and Drug Administration (FDA) in April 2016.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access